4//SEC Filing
Versartis, Inc. 4
Accession 0001209191-14-023493
CIK 0001513818operating
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 5:10 PM ET
Size
32.8 KB
Accession
0001209191-14-023493
Insider Transaction Report
Form 4
Versartis, Inc.VSAR
Advent Life Sciences LLP
10% Owner
Transactions
- Conversion
Common Stock
2014-03-26+1,258,086→ 1,258,086 total(indirect: See FN) - Conversion
Common Stock
2014-03-26+489,253→ 1,747,339 total(indirect: See FN) - Conversion
Common Stock
2014-03-26+176,813→ 1,924,152 total(indirect: See FN) - Conversion
Common Stock
2014-03-26+78,228→ 2,002,380 total(indirect: See FN) - Conversion
Common Stock
2014-03-26+154,178→ 2,156,558 total(indirect: See FN) - Purchase
Common Stock
2014-03-26$21.00/sh+60,000$1,260,000→ 2,216,558 total(indirect: See FN) - Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2014-03-26−506,376→ 0 total(indirect: See FN)Exercise: $0.45Exp: 2014-03-26→ Series B Convertible Preferred Stock (506,376 underlying) - Exercise of In-Money
Series B Convertible Preferred Stock
2014-03-26+506,376→ 14,468,020 total(indirect: See FN)→ Common Stock (44,031 underlying) - Conversion
Series B Convertible Preferred Stock
2014-03-26−14,468,020→ 0 total(indirect: See FN)→ Common Stock (1,258,086 underlying) - Conversion
Series C Convertible Preferred Stock
2014-03-26−5,626,413→ 0 total(indirect: See FN)→ Common Stock (489,253 underlying) - Conversion
Series D-1 Convertible Preferred Stock
2014-03-26−2,033,350→ 0 total(indirect: See FN)→ Common Stock (176,813 underlying) - Conversion
Series D-2 Convertible Preferred Stock
2014-03-26−899,619→ 0 total(indirect: See FN)→ Common Stock (78,228 underlying) - Conversion
Series E Convertible Preferred Stock
2014-03-26−1,773,049→ 0 total(indirect: See FN)→ Common Stock (154,178 underlying)
Footnotes (4)
- [F1]In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for-11.5 basis.
- [F2]Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund.
- [F3]Immediately exercisable. In connection with the closing of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis if the warrant is not otherwise exercised prior to such closing.
- [F4]The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, The Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.
Documents
Issuer
Versartis, Inc.
CIK 0001513818
Entity typeoperating
IncorporatedTX
Related Parties
1- filerCIK 0001513818
Filing Metadata
- Form type
- 4
- Filed
- Mar 26, 8:00 PM ET
- Accepted
- Mar 27, 5:10 PM ET
- Size
- 32.8 KB